Skip to main content
. 2017 Jun 13;12(6):e0178801. doi: 10.1371/journal.pone.0178801

Fig 4. Kaplan-Meier BKPyV nephropathy in time.

Fig 4

There was a significant difference in the incidence of BKPyVAN over 24 months between the two treatment groups (p = 0.03). CsAM: cyclosporine A with MPS or MMF, TacM: tacrolimus with MPS or MMF. CsAM: cyclosporine A with or without prednisone and MPS or MMF, TacM: tacrolimus with or without prednisone and MPS or MMF, BKPyVAN: BK polyomavirus nephropathy, BPAR: Biopsy proven acute rejection.